Literature DB >> 26109684

Bortezomib-induced acute interstitial nephritis.

Wisit Cheungpasitporn1, Nelson Leung2, S Vincent Rajkumar3, Lynn D Cornell4, Sanjeev Sethi4, Andrea Angioi1, Fernando C Fervenza1.   

Abstract

Acute interstitial nephritis (AIN) is one of the important causes of acute kidney injury (AKI) resulting from inflammatory tubulointerstitial injury induced by medications, infections and systemic diseases. Bortezomib has been increasingly used especially in renal related indications such as multiple myeloma and monoclonal gammopathy of renal significance. Severe allergic reactions from bortezomib treatment including AIN have not been described in the literature. We report a 47-year-old white man who developed biopsy-proven allergic AIN after treatment with bortezomib for his C3 glomerulonephritis. The patient's kidney function improved after treatment with glucocorticoid therapy and discontinuation of bortezomib, but worsened with recurrent AKI episode after re-initiation of bortezomib. His renal function improved after glucocorticoid therapy and discontinuation of bortezomib. To our knowledge, this is the first report of a biopsy-proven AIN from bortezomib.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  C3 glomerulonephritis; acute interstitial nephritis; bortezomib; monoclonal gammopathy; nephrotoxicity

Mesh:

Substances:

Year:  2015        PMID: 26109684     DOI: 10.1093/ndt/gfv222

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

Review 1.  Management of nephrotoxicity of chemotherapy and targeted agents: 2020.

Authors:  Varsha Chiruvella; Pavan Annamaraju; Achuta K Guddati
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

Review 3.  Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.

Authors:  Rimda Wanchoo; Ala Abudayyeh; Mona Doshi; Amaka Edeani; Ilya G Glezerman; Divya Monga; Mitchell Rosner; Kenar D Jhaveri
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-21       Impact factor: 8.237

4.  Acute Tubular Necrosis in a Patient With Myeloma Treated With Carfilzomib.

Authors:  Vladimir Liberman; Vivette D D'Agati; Naveed N Masani; James Drakakis; Joseph Mattana
Journal:  Kidney Int Rep       Date:  2016-06-23

5.  Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits in a young woman: A case report.

Authors:  Zi-Gan Xu; Wei-Long Li; Xi Wang; Shu-Yuan Zhang; Ying-Wei Zhang; Xing Wei; Chun-Di Li; Ping Zeng; Shao-Dong Luan
Journal:  World J Clin Cases       Date:  2021-04-06       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.